Back to resultsHigh Doses of 4-aminopyridine in Clinically Complete Chronic Spinal Cord Injury Patients.
Primary Purpose
Spinal Cord Injuries, Chronic
Status
Active
Phase
Phase 3
Locations
Mexico
Study Type
Interventional
Intervention
4-Aminopyridine
Placebo oral capsule
Sponsored by
About this trial
This is an interventional treatment trial for Spinal Cord Injuries focused on measuring 4-Aminopyridine, erectile function, tetraplegia, rehabilitation, questionnaires, paraplegia
Eligibility Criteria
Inclusion Criteria: Patients with spinal cord injury (SCI) will be eligible for the study if they meet the following criteria:
- Chronic AIS A tetraplegia or paraplegia for more tan 2 years before the study begin.
- MRI showing cord continuity.
- Neurologic Injury level of C4-T12.
- Medically stable and able to breathe independently.
- Stable neurologic deficits for more than 60 days before the study.
- The absence of antiepileptic antecedent and electroencephalogram without epileptic activity.
- They have maintained some type of rehabilitation after injury in the affected limbs and paralyzed extremities without passive limitations (healthy joints)
- For females: postmenopausal or surgically sterile, or using an acceptable method of birth control.
Exclusion Criteria:
- Pressure ulcers, skin infections, or phlebitis
- History of cardiovascular disease (syncope, arrhythmia, or myocardial infarction within the last two years), systolic blood pressure greater than 150 or less than 70 mm Hg, diastolic blood pressure greater than 110 or less than 50 mm Hg, or heart rate greater than 110 or less than 50 beats/minute; impaired hepatic function (total hepatic enzyme or bilirubin levels greater than 2 times the upper limits of normal) or impaired renal function (creatinine level greater than 2 times the upper limits of normal) less than 6 months before the study
- Know allergy to pyridine-containing drugs
- Neurologic, degenerative, or psychiatric disorders that would impair the patient's ability to complete the protocol
- Any illness or abnormality that would jeopardize patient safety or interfere with the conduct of the study
- Inability to discontinue excluded concomitant drug therapy
- Were pregnant or lactating
- Had received any other investigational drug less tan 30 days before the study
- History of drug or alcohol abuse
- Treatment with and anti-spasticity compound and could not maintain a stable daily dosage
- Had received any drug known to cause significant major organ toxicity less tan 3 months before the study
- Peripheral neuropathy
- Treatment with corticosteroids
Sites / Locations
- Hospital de Especialidades, CMN Siglo XXI
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Treatment with 4-aminopyridine
Placebo oral capsule
Arm Description
The 4-aminopyridine will be administered in the form of gelatin capsules containing 4-aminopyridine 10 mg and microcrystalline cellulose as excipient. The dose of 4-aminopyridine will increase 10 mg / every 2 to 4 weeks until reaching the maximum dose proposed by weight ( maximum 1 mg / kg / d).
Patients randomized to the placebo sequence will receive placebo in the same way as those who will take 4-AP. They will be blinded to the fact that they are taking placebo and the capsules will be identical in appearance to the intervention capsules.
Outcomes
Primary Outcome Measures
Changes in Sensory Function
This function will be examined using the ASIA International Standards for the Neurological and Functional Classification of Spinal Cord Injury. Sensory function will be evaluated and qualify for two modes, pin prick / light touch in all dermatomes. The first one will be measured with the sharp and blunt end of a safety pin and the last one will be evaluated with a cotton ball. A scale of 3 points (0- 2) will be used depending on whether the modality is normal (2), diminished (1) or absent (0). A score of 2 for each of the 28 key sensory points tested on each side of the body would result in a maximum score of 56 for pin prick, 56 for light touch, and a total of 112, higher values represent a better outcome.
Changes in Motor function
Motor function will be examined using the ASIA International Standards for the Neurological and Functional Classification of Spinal Cord Injury. Muscle strength will be evaluated in each of the 20 key muscles, five in each limb, representing segments of the spinal cord C5 through T1 and L2 through S1, using a six-point rating scale (0-5). There is a maximum score of 25 for each extremity, totaling 50 for the upper limbs and 50 for the lower limbs. Changes in motor score (total range from 0 to 100, higher values represent a better outcome).
Changes in the functional assement of Spinal Cord Independence
The Spinal Cord Independence Measure version III (SCIM III) has 16 questions on self-care, respiratory and sphincter management and mobility in and out of home, which ranges from 0 (total dependence) to 100 points (total Independence).
Changes in the Sphincters function
The function of the anal sphincter and the bladder will be evaluated. The anal function will be qualified as a sensation when the patient can differentiate when the rectum is full and ready to empty and control when the patient can stop the fecal evacuation with enough time to reach the bathroom and eliminate the fecal material. The function of the bladder will be classified in the same way as the anal function. Positive or negative will be the final result of sensation and control.
Change of overall quality of life score as measured by Short Form-36 (SF-36)
The Short Form-36 (SF-36) has 36 questions. Each question has a score, which will be transformed into a 0 to 100 scale, where 0 corresponds to "the worst health state" and 100 to "the best health state".
Changes in Mean International Index of Erectile Function
The international Index of Erectile Function (IIEF) contains 15 questions, rated from 0 or 1 to 5, yielding an overall score of 5-75 points. A score of 1-10 indicates severe erectile dysfunction, 11-16 moderate dysfunction, 17-25 mild dysfunction, and greater than 25 "normal" function.
Incidence of Treatment-Emergent Adverse Events (Safety)
Safety will be measured by occurrence of Treatment-Emergent Adverse Events (TRAEs); data will represent the number of participants with abnormal laboratory values and/or adverse events that are related to treatment.
Secondary Outcome Measures
Full Information
NCT ID
NCT03899584
First Posted
February 13, 2019
Last Updated
February 18, 2021
Sponsor
Coordinación de Investigación en Salud, Mexico
1. Study Identification
Unique Protocol Identification Number
NCT03899584
Brief Title
High Doses of 4-aminopyridine in Clinically Complete Chronic Spinal Cord Injury Patients.
Official Title
Quality of Life, Efficacy and Safety of High Doses of 4-aminopyridine in Patients With Clinically Complete Chronic Spinal Cord Injury: Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
February 2021
Overall Recruitment Status
Active, not recruiting
Study Start Date
July 17, 2019 (Actual)
Primary Completion Date
December 2022 (Anticipated)
Study Completion Date
December 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Coordinación de Investigación en Salud, Mexico
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
150 patients with clinically complete chronic spinal cord Injury will be included in a randomized, parallel, placebo controlled, multi-centric, phase III trial. Patients will be evaluated before starting the medication, and at the end of the treatment in the locomotor, sensory, grade of independence, sensitivity and control of bladder and anal sphincters, quality of life, and psychogenic erection in males. Patients will be divided randomly into two groups where one will receive placebo and the other one 4-Aminopyridine (4-AP) in a maximum of 30 weeks in increasing doses.
Detailed Description
Consecutive patients with chronic AIS A tetraplegic or paraplegic with an MRI showing cord continuity will be recruited in the departments of neurology, neurosurgery or rehabilitation from hospitals of Social Security Mexican Institute (IMSS) in 8 states . Just patients who meeting inclusion criteria, will be selected for the study until reach 150. After signing an informed consent, they will be randomized into 75 for the intervention arm and 75 for the placebo arm. All patients will receive capsules for daily consumption according to their assignment. They will receive ascending doses of the drug starting with 10 milligrams and progressively increasing every 2 to 4 weeks 10 mg until reaching the maximum dose proposed according to weight (maximum 1 mg/kg/d). Questionnaires and functional evaluations will be administered at the beginning of the study, and at the end of the treatment to evaluate the efficacy. The evaluations include the International Standards for Neurological Classification of Spinal Cord Injury motor and sensory Scale, the Spinal Cord Injury Independence Measure (SCIM III), quality of life (SF-36), sphincter bladder/anal sensation/control in both genders and psychogenic erection in males as primary outcomes.
After the follow-up period, all test results will be analyzed and compared to determine the efficacy and safety of 4-aminopyridine. The Mann-Whitney U and Chi-square test will be used for statistical analysis.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Spinal Cord Injuries, Chronic
Keywords
4-Aminopyridine, erectile function, tetraplegia, rehabilitation, questionnaires, paraplegia
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
150 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Treatment with 4-aminopyridine
Arm Type
Active Comparator
Arm Description
The 4-aminopyridine will be administered in the form of gelatin capsules containing 4-aminopyridine 10 mg and microcrystalline cellulose as excipient. The dose of 4-aminopyridine will increase 10 mg / every 2 to 4 weeks until reaching the maximum dose proposed by weight ( maximum 1 mg / kg / d).
Arm Title
Placebo oral capsule
Arm Type
Placebo Comparator
Arm Description
Patients randomized to the placebo sequence will receive placebo in the same way as those who will take 4-AP. They will be blinded to the fact that they are taking placebo and the capsules will be identical in appearance to the intervention capsules.
Intervention Type
Drug
Intervention Name(s)
4-Aminopyridine
Other Intervention Name(s)
4-AP
Intervention Description
Each patient will take 10 mg per kilogram of weight (example: a person weighing 60 kg, will take two capsules three times a day after meals, for a total of 6 capsules / day). Each capsule will contain 10 milligrams of 4-Aminopyridine that will allow to be administered sequentially at progressively higher doses / day. The dose of 4-aminopyridine will increase 10 mg / 2 to 4 weeks.
Intervention Type
Drug
Intervention Name(s)
Placebo oral capsule
Other Intervention Name(s)
Microcrystalline cellulose
Intervention Description
The placebo arm will include a placebo of microcrystalline cellulose.
Primary Outcome Measure Information:
Title
Changes in Sensory Function
Description
This function will be examined using the ASIA International Standards for the Neurological and Functional Classification of Spinal Cord Injury. Sensory function will be evaluated and qualify for two modes, pin prick / light touch in all dermatomes. The first one will be measured with the sharp and blunt end of a safety pin and the last one will be evaluated with a cotton ball. A scale of 3 points (0- 2) will be used depending on whether the modality is normal (2), diminished (1) or absent (0). A score of 2 for each of the 28 key sensory points tested on each side of the body would result in a maximum score of 56 for pin prick, 56 for light touch, and a total of 112, higher values represent a better outcome.
Time Frame
From baseline at 6 months after treatment
Title
Changes in Motor function
Description
Motor function will be examined using the ASIA International Standards for the Neurological and Functional Classification of Spinal Cord Injury. Muscle strength will be evaluated in each of the 20 key muscles, five in each limb, representing segments of the spinal cord C5 through T1 and L2 through S1, using a six-point rating scale (0-5). There is a maximum score of 25 for each extremity, totaling 50 for the upper limbs and 50 for the lower limbs. Changes in motor score (total range from 0 to 100, higher values represent a better outcome).
Time Frame
From baseline at 6 months after treatment
Title
Changes in the functional assement of Spinal Cord Independence
Description
The Spinal Cord Independence Measure version III (SCIM III) has 16 questions on self-care, respiratory and sphincter management and mobility in and out of home, which ranges from 0 (total dependence) to 100 points (total Independence).
Time Frame
From baseline at 6 months after treatment
Title
Changes in the Sphincters function
Description
The function of the anal sphincter and the bladder will be evaluated. The anal function will be qualified as a sensation when the patient can differentiate when the rectum is full and ready to empty and control when the patient can stop the fecal evacuation with enough time to reach the bathroom and eliminate the fecal material. The function of the bladder will be classified in the same way as the anal function. Positive or negative will be the final result of sensation and control.
Time Frame
From baseline at 6 months after treatment
Title
Change of overall quality of life score as measured by Short Form-36 (SF-36)
Description
The Short Form-36 (SF-36) has 36 questions. Each question has a score, which will be transformed into a 0 to 100 scale, where 0 corresponds to "the worst health state" and 100 to "the best health state".
Time Frame
From baseline at 6 months after treatment
Title
Changes in Mean International Index of Erectile Function
Description
The international Index of Erectile Function (IIEF) contains 15 questions, rated from 0 or 1 to 5, yielding an overall score of 5-75 points. A score of 1-10 indicates severe erectile dysfunction, 11-16 moderate dysfunction, 17-25 mild dysfunction, and greater than 25 "normal" function.
Time Frame
From baseline at 6 months after treatment
Title
Incidence of Treatment-Emergent Adverse Events (Safety)
Description
Safety will be measured by occurrence of Treatment-Emergent Adverse Events (TRAEs); data will represent the number of participants with abnormal laboratory values and/or adverse events that are related to treatment.
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with spinal cord injury (SCI) will be eligible for the study if they meet the following criteria:
Chronic AIS A tetraplegia or paraplegia for more tan 2 years before the study begin.
MRI showing cord continuity.
Neurologic Injury level of C4-T12.
Medically stable and able to breathe independently.
Stable neurologic deficits for more than 60 days before the study.
The absence of antiepileptic antecedent and electroencephalogram without epileptic activity.
They have maintained some type of rehabilitation after injury in the affected limbs and paralyzed extremities without passive limitations (healthy joints)
For females: postmenopausal or surgically sterile, or using an acceptable method of birth control.
Exclusion Criteria:
Pressure ulcers, skin infections, or phlebitis
History of cardiovascular disease (syncope, arrhythmia, or myocardial infarction within the last two years), systolic blood pressure greater than 150 or less than 70 mm Hg, diastolic blood pressure greater than 110 or less than 50 mm Hg, or heart rate greater than 110 or less than 50 beats/minute; impaired hepatic function (total hepatic enzyme or bilirubin levels greater than 2 times the upper limits of normal) or impaired renal function (creatinine level greater than 2 times the upper limits of normal) less than 6 months before the study
Know allergy to pyridine-containing drugs
Neurologic, degenerative, or psychiatric disorders that would impair the patient's ability to complete the protocol
Any illness or abnormality that would jeopardize patient safety or interfere with the conduct of the study
Inability to discontinue excluded concomitant drug therapy
Were pregnant or lactating
Had received any other investigational drug less tan 30 days before the study
History of drug or alcohol abuse
Treatment with and anti-spasticity compound and could not maintain a stable daily dosage
Had received any drug known to cause significant major organ toxicity less tan 3 months before the study
Peripheral neuropathy
Treatment with corticosteroids
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Martín Paredes Cruz, MSc
Organizational Affiliation
Instituto Mexicano del Seguro Social
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Israel Grijalva Otero, PhD
Organizational Affiliation
Instituto Mexicano del Seguro Social
Official's Role
Study Director
Facility Information:
Facility Name
Hospital de Especialidades, CMN Siglo XXI
City
Mexico City
ZIP/Postal Code
06725
Country
Mexico
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
8320728
Citation
Hansebout RR, Blight AR, Fawcett S, Reddy K. 4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients. J Neurotrauma. 1993 Spring;10(1):1-18. doi: 10.1089/neu.1993.10.1.
Results Reference
background
PubMed Identifier
8320729
Citation
Waxman SG. Aminopyridines and the treatment of spinal cord injury. J Neurotrauma. 1993 Spring;10(1):19-24. doi: 10.1089/neu.1993.10.19. No abstract available.
Results Reference
background
PubMed Identifier
8493036
Citation
Hayes KC, Blight AR, Potter PJ, Allatt RD, Hsieh JT, Wolfe DL, Lam S, Hamilton JT. Preclinical trial of 4-aminopyridine in patients with chronic spinal cord injury. Paraplegia. 1993 Apr;31(4):216-24. doi: 10.1038/sc.1993.40.
Results Reference
background
PubMed Identifier
7837283
Citation
Hayes KC, Potter PJ, Wolfe DL, Hsieh JT, Delaney GA, Blight AR. 4-Aminopyridine-sensitive neurologic deficits in patients with spinal cord injury. J Neurotrauma. 1994 Aug;11(4):433-46. doi: 10.1089/neu.1994.11.433.
Results Reference
background
PubMed Identifier
8938604
Citation
Zeidman SM, Ling GS, Ducker TB, Ellenbogen RG. Clinical applications of pharmacologic therapies for spinal cord injury. J Spinal Disord. 1996 Oct;9(5):367-80.
Results Reference
background
PubMed Identifier
9554012
Citation
Potter PJ, Hayes KC, Hsieh JT, Delaney GA, Segal JL. Sustained improvements in neurological function in spinal cord injured patients treated with oral 4-aminopyridine: three cases. Spinal Cord. 1998 Mar;36(3):147-55. doi: 10.1038/sj.sc.3100559.
Results Reference
background
PubMed Identifier
21551756
Citation
Hayes KC. 4-Aminopyridine and spinal cord injury: a review. Restor Neurol Neurosci. 1994 Jan 1;6(4):259-70. doi: 10.3233/RNN-1994-6401.
Results Reference
background
PubMed Identifier
10762192
Citation
Donovan WH, Halter JA, Graves DE, Blight AR, Calvillo O, McCann MT, Sherwood AM, Castillo T, Parsons KC, Strayer JR. Intravenous infusion of 4-AP in chronic spinal cord injured subjects. Spinal Cord. 2000 Jan;38(1):7-15. doi: 10.1038/sj.sc.3100931.
Results Reference
background
PubMed Identifier
11569894
Citation
van der Bruggen MA, Huisman HB, Beckerman H, Bertelsmann FW, Polman CH, Lankhorst GJ. Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury. J Neurol. 2001 Aug;248(8):665-71. doi: 10.1007/s004150170111.
Results Reference
background
PubMed Identifier
11526982
Citation
Wolfe DL, Hayes KC, Hsieh JT, Potter PJ. Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury: a double-blinded, placebo-controlled crossover trial. J Neurotrauma. 2001 Aug;18(8):757-71. doi: 10.1089/089771501316919120.
Results Reference
background
PubMed Identifier
12885095
Citation
Grijalva I, Guizar-Sahagun G, Castaneda-Hernandez G, Mino D, Maldonado-Julian H, Vidal-Cantu G, Ibarra A, Serra O, Salgado-Ceballos H, Arenas-Hernandez R. Efficacy and safety of 4-aminopyridine in patients with long-term spinal cord injury: a randomized, double-blind, placebo-controlled trial. Pharmacotherapy. 2003 Jul;23(7):823-34. doi: 10.1592/phco.23.7.823.32731.
Results Reference
background
PubMed Identifier
14970964
Citation
Hayes KC, Potter PJ, Hsieh JT, Katz MA, Blight AR, Cohen R. Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury. Arch Phys Med Rehabil. 2004 Jan;85(1):29-34. doi: 10.1016/s0003-9993(03)00651-8.
Results Reference
background
PubMed Identifier
15356676
Citation
DeForge D, Nymark J, Lemaire E, Gardner S, Hunt M, Martel L, Curran D, Barbeau H. Effect of 4-aminopyridine on gait in ambulatory spinal cord injuries: a double-blind, placebo-controlled, crossover trial. Spinal Cord. 2004 Dec;42(12):674-85. doi: 10.1038/sj.sc.3101653.
Results Reference
background
PubMed Identifier
16773037
Citation
Cardenas DD, Ditunno J, Graziani V, Jackson AB, Lammertse D, Potter P, Sipski M, Cohen R, Blight AR. Phase 2 trial of sustained-release fampridine in chronic spinal cord injury. Spinal Cord. 2007 Feb;45(2):158-68. doi: 10.1038/sj.sc.3101947. Epub 2006 Jun 13.
Results Reference
background
PubMed Identifier
21167397
Citation
Grijalva I, Garcia-Perez A, Diaz J, Aguilar S, Mino D, Santiago-Rodriguez E, Guizar-Sahagun G, Castaneda-Hernandez G, Maldonado-Julian H, Madrazo I. High doses of 4-aminopyridine improve functionality in chronic complete spinal cord injury patients with MRI evidence of cord continuity. Arch Med Res. 2010 Oct;41(7):567-75. doi: 10.1016/j.arcmed.2010.10.001.
Results Reference
background
PubMed Identifier
24216616
Citation
Cardenas DD, Ditunno JF, Graziani V, McLain AB, Lammertse DP, Potter PJ, Alexander MS, Cohen R, Blight AR. Two phase 3, multicenter, randomized, placebo-controlled clinical trials of fampridine-SR for treatment of spasticity in chronic spinal cord injury. Spinal Cord. 2014 Jan;52(1):70-6. doi: 10.1038/sc.2013.137. Epub 2013 Nov 12.
Results Reference
background
Learn more about this trial
High Doses of 4-aminopyridine in Clinically Complete Chronic Spinal Cord Injury Patients.
We'll reach out to this number within 24 hrs